Lilly rides Mounjaro, Zepbound to better
Time:2024-05-01 05:16:48 Source:worldViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
You may also like
- Welcome to stench ground zero: The village where an unspeakable two
- Cleveland Guardians are off to a blazing start with MLB's best record under rookie manager
- Missouri lawmakers again try to kick Planned Parenthood off Medicaid
- Mystery as Camp Lejeune Marine sergeant, 23, dies in late
- Democrats vow to protect Speaker Mike Johnson from being ousted from office
- North Korean leader Kim leads rocket drills that simulate a nuclear counterattack against enemies
- Storm relief and funding for programs related to Maine's deadliest
- An adored ostrich at a Kansas zoo has died after swallowing a staff member's keys
- Alicia Keys, Brian d’Arcy James, Daniel Radcliffe and more react to earning Tony Award nominations